Ignite Creation Date:
2024-05-05 @ 12:10 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00263016
Status:
TERMINATED
Last Update Posted:
2008-03-20
First Post:
2005-12-06
Brief Title:
Docetaxel in Non Small Cell Lung Cancer NSCLC
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
A Phase II Pilot Study of Combination of Irinotecan and Cisplatin in DocetaxelCisplatin-Responsive Advanced Non-Small Cell Lung Cancer
Status:
TERMINATED
Status Verified Date:
2008-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Slow recruitment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primary Objective
To compare the tumour response rate of combination chemotherapy irinotecancisplatin IC versus docetaxelcisplatin DC in advanced NSCLC patients who responded to 3 courses of docetaxelcisplatin
Secondary Objectives
To compare the time to progression after chemotherapy treatment between the IC and DC arms of treatment
To compare the toxicity profile of the IC and DC arms of treatment
To compare the tumour response rate of combination chemotherapy irinotecancisplatin IC versus docetaxelcisplatin DC in advanced NSCLC patients who responded to 3 courses of docetaxelcisplatin
Secondary Objectives
To compare the time to progression after chemotherapy treatment between the IC and DC arms of treatment
To compare the toxicity profile of the IC and DC arms of treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None